Top Story Today
Argenx's Sjogren's Trial Stopped for Futility While Its Celiac Bet Quietly Delivered
An independent monitoring board pulled the plug on argenx's Phase 3 Sjogren's trial of Vyvgart, concluding the drug would essentially never hit its primary endpoint. Shares cratered 11% to 16%, erasing billions in market cap. But buried in the wreckage: positive Phase 2 data for FB102 in celiac disease, where the drug significantly preserved gut health during a controlled gluten challenge. Sjogren's has now defeated roughly 30 randomized trials across multiple drug classes, making it one of autoimmune's most humbling targets. The celiac win gives argenx a differentiated pipeline asset, but investors weren't in a mood for silver linings.
Why it matters: Sjogren's disease continues to defy every drug class thrown at it, raising hard questions about trial design in heterogeneous autoimmune conditions. For argenx, the failure shrinks the Vyvgart addressable market while the celiac data opens a new, if earlier-stage, opportunity outside the FcRn franchise.
Read more →Clinical and Regulatory
A Lung Drug That Doesn't Just Slow the Damage. It Might Undo It.
In a disease where every approved drug just slows the scarring, Endeavor BioMedicines reported Phase 2b data suggesting its Hedgehog pathway inhibitor taladegib actually improved lung function from baseline. The 213-patient trial met its primary endpoint, with imaging biomarkers moving in the right direction across the board. If confirmed in Phase 3, this could be the first IPF therapy to reverse fibrosis rather than manage it.
Read more →Tecentriq Becomes the First Checkpoint Inhibitor Approved for Early-Stage Colon Cancer
The FDA approved Genentech's Tecentriq plus chemo for stage III mismatch repair-deficient colon cancer after surgery, cutting recurrence risk roughly in half. It's the first immunotherapy to land an adjuvant colorectal label, moving checkpoint inhibitors from last-resort metastatic treatment to the post-surgical "make sure it doesn't come back" setting. Genentech now owns a competitive vacuum no rival has filled.
Read more →Four Deaths Put a Novel Schizophrenia Drug's Future in Question
The FDA flagged four patient deaths (versus one on placebo) in Newron's evenamide program and kept its U.S. clinical hold in place. Evenamide targets glutamate signaling rather than dopamine, making it one of the few genuinely novel schizophrenia mechanisms in development. A critical data readout from ex-U.S. sites is expected before the end of 2026, and the outcome could determine whether the glutamate hypothesis finally produces an approved drug.
Read more →Deals and M&A
Thermo Fisher Drops $8.9 Billion on a Company You've Probably Never Heard Of
Thermo Fisher agreed to pay up to $9.4 billion for Clario Holdings, a clinical trial data platform that has quietly touched 70% of all novel drugs approved by the FDA and EMA over the past decade. Combined with its 2021 PPD acquisition, Thermo Fisher is assembling something that looks less like a tools company and more like the operating system of drug development.
Read more →Viatris Bets $1.65 Billion That Generics Alone Won't Cut It
One of the world's biggest generics companies is paying $1.65 billion in cash for Pacira BioSciences and its non-opioid pain portfolio, headlined by EXPAREL ($575 million in annual sales). The 44.8% premium says something about how urgently Viatris needs higher-margin branded products to escape the generics treadmill of relentless pricing pressure.
Read more →Roche Signs Another China Deal, This Time for Molecular Glue Discovery
Roche partnered with Defand Therapeutics, a two-year-old Hangzhou startup with zero clinical trials, on a deal worth up to $1 billion to discover molecular glue cancer drugs. The rest is milestones. It's part of Roche's recent streak of China collaborations, and it signals that big pharma increasingly views Chinese biotechs as innovation engines, not just late-stage licensing targets.
Read more →Novo Nordisk Pays $1.3 Billion to Turn Weekly GLP-1 Shots Into Quarterly Ones
Novo licensed Nanexa's PharmaShell technology, which coats drug particles atom by atom to create slow-release depots under the skin. The deal covers up to five programs across obesity and diabetes for up to $1.3 billion. In a market where dosing convenience is becoming the key differentiator, turning 52 annual injections into four could be the next GLP-1 competitive moat.
Read more →Policy and Industry
Big Pharma Got a Hall Pass on Drug Tariffs. Small Biotechs Got the Bill.
Trump's 100% tariffs on imported patented drugs came with plenty of escape hatches for large pharma companies that can negotiate pricing deals or pledge billion-dollar factories. Small biotechs, many reliant on overseas contract manufacturers, are stuck navigating an exemption maze with no clear guidance. Trade groups warn the policy could push early-stage programs off the table entirely, narrowing the future pipeline.
Read more →TikTok's Parent Company Now Wants to Make Your Medicine
ByteDance spun out its five-year internal drug discovery unit into Anew Labs, which closed $290 million in funding at a $1.5 billion valuation. The AI biotech is building an "agentic" discovery engine across small molecules, antibodies, and nanobodies, with immunology programs already in lead optimization. ByteDance retains a 56% stake, making the TikTok parent a majority owner of a bona fide drug company.
Read more →